



Luminous Mind, Inc. Announces U.S. Patent for Non-Hallucinogenic Psychedelic Mushrooms

Luminous Mind, Inc. seeks strategic partnerships with leading nutraceutical, supplement, pharmaceutical, and venture groups to bring breakthrough products to market, potentially opening a billion-dollar-plus opportunity.

Boston – September 30, 2026. Luminous Mind, Inc. (LMI), a biotechnology company focused on impactful mental health products, announces the issuance of [U.S. Patent No. 12,697,362](#), following its grant in Europe. This foundational patent, which enables the production of non-hallucinogenic psychedelic fungi, supports the development of a portfolio of consumer products with significant market potential. Grand View Research estimates the 2025 global functional mushroom market at \$38.2 billion.



LMI's patent recognizes that psilocybin-containing mushrooms produce other highly beneficial compounds (secondary metabolites and active fungal molecules) that are usually overshadowed by the hallucinogen. Removing the psilocybin yields products that offer these potential benefits without causing hallucinations.

Louis Herlands, Ph.D., CEO, expressed his enthusiasm about the patent: *"Sometimes less is more. This invention paves the way to provide broad access to the nutraceutical benefits of some of the most biosynthetically creative mushrooms. My analogy is that this is like instantly domesticating the tomato or the potato from their toxic wild ancestors and making them nutritionally available to everyone."*

For more detailed information, please review the commentary: ["When it comes to magic mushrooms, less is more."](#)

Because LMI's patented technology yields non-hallucinogenic product candidates, it opens the door to commercialization in a large market. Over the longer term, this patent also sets the stage for developing pharmaceuticals through synthetic biology.

Myles Axton, Ph.D., genetics researcher at LMI and former Chief Editor of *Nature Genetics*, said: *"I am most excited that this genetic innovation will let mushrooms produce useful levels of over a dozen amazing compounds that would be present only in tiny amounts in a psychedelic mushroom, and which we might otherwise obtain only under the most restricted lab conditions."*

Companies interested in strategic partnerships to access this technology are invited to contact the LMI Business Development Department.

About Luminous Mind Inc.

Luminous Mind Inc., focused on central nervous system (CNS) disorders, applies a rigorous therapeutic discovery and development process that includes repurposing existing, abandoned, and developmental compounds for new indications. Groundbreaking scientific insights in neuroscience, genetics, systems biology, and brain circuitry, together with powerful new tools, drive its discovery efforts. For additional information, please visit www.LuminousMindInc.com.

Contact:

Business Development
BD@LuminousMindInc.com
800-816-9630 x712
Cambridge, MA